PVR and neoplasm: As these molecules have the peculiar feature of binding both DNAM-1 and TIGIT, an inhibitory receptor on NK cells, the expression of CD112 and CD155 by tumor cells could potentially play a dual role either by triggering or dampening NK cell effector functions.